• First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC
  • FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer
  • FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers
  • FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
  • EMA Asked to Conditionally Approve Gliovac, Cancer Vaccine, for Recurrent Glioblastoma
  • FDA Approves Keytruda for Advanced Squamous Cell Skin Cancer
  • Keytruda Approved in China as Second-line Therapy for Advanced Esophageal Cancers
  • Imfinzi Plus Chemo Showing 2-year Survival Benefit in Advanced SCLC Study
  • Keytruda Approved to Treat Solid Tumors With High Mutational Burden
  • Bavencio Shows Benefit as 1st-line Maintenance Therapy for Bladder Cancer in Phase 3 Trial
  • Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track
  • FDA Approves Opdivo for Advanced Esophageal Cancer